WASHINGTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC, a nationally recognized leader in investor protection, announces that investors who purchased shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) in the company’s September 2024 initial public offering may seek to lead a federal securities class action. The deadline to move for appointment as lead plaintiff is June 16, 2025. [Click here for information about joining the class action] If you’d like to discuss this matter or your rights before signing up, please contact Molly J. Bowen, a partner at Cohen Milstein, at (202) 408-4600 or [email protected]. The Lawsuit Filed in the U.S. District Court for the District of Massachusetts, the complaint alleges that Zenas and its IPO underwriters misrepresented the company’s financial outlook. Zenas BioPharma stated in its IPO materials that it could fund operations for 24 months. However, just weeks later, its Q3 2024 filing disclosed a funding window of only 12 months—cutting projections in half. ZBIO stock fell nearly 49%, closing at $8.72 on April 15, 2025. Why Lead Plaintiff Matters Investors with substantial losses can help guide and direct the litigation. Serving as lead plaintiff enables shareholders to influence litigation strategy and potential recovery. Serving in this role is not required to participate in any eventual settlement. About Cohen Milstein Cohen Milstein has a national reputation for excellence in securities litigation, recovering billions for investors, including a recent $1 billion settlement in In re Wells Fargo Securities Litigation. The firm is recognized annually by The Legal 500, Chambers USA, and Law360 for its leadership in complex securities class actions. CONTACT: Molly Bowen, Esq. Licensed in DC, Florida, and Ohio Cohen Milstein Sellers & Toll PLLC 1100 New York Avenue, N.W., Fifth Floor Washington, D.C. 20005 Phone: (888) 240-0775 or (202) 408-4600 Email: [email protected] Website: www.cohenmilstein.com Attorney Advertising. Prior results do not guarantee a similar outcomes.
Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...